title: Antioxidant status in patients with psoriasis.
abstract: Psoriasis is a chronic inflammatory skin disease with an unknown aetiology that has been associated with abnormal plasma lipid metabolism and oxidative stress. There are controversial results in the previous studies investigating oxidant/antioxidant systems in psoriasis.The aim of this work was to evaluate the plasma levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), total bilirubin (T. Bili), direct bilirubin (D. Bili), uric acid (UA), apolipoproteins (ApoA1 and ApoB), Lp(a) and activities of paraxonase 1 (PON1) in 100 patients with psoriasis and 100 controls, and to look for a correlation between these parameters in psoriasis.PON1, bilirubin and UA were measured spectrophotometrically, MDA by the high-performance liquid chromatography method, apolipoproteins and Lp(a) by immunoprecipitation assays, and lipid and other biochemical parameters were determined by routine laboratory methods.In patients with psoriasis, there was a significant decrease in PON1, SOD and CAT activities (P < 0.05) and an increase in MDA levels (P < 0.01). Also, the levels of bilirubin (total and direct) and UA were decreased in patients with psoriasis but were not significant (P > 0.05).These results suggest that psoriasis was in a state of oxidative stress and that the protective effects of high-density lipoprotein against atherosclerosis may be dependent on PON1 activity. Moreover, there is a negative correlation between antioxidant with Lp(a), apoB and MDA levels, suggesting that subjects with higher levels of Lp(a) and apoB and lower levels of antioxidant are more exposed to oxidative damage. These findings may explain in part the reported increase in cardiovascular mortality in psoriasis.
authors.forename: Houshang
authors.initials: H
authors.lastname: Nemati
authors.forename: Nemati
authors.initials: N
authors.lastname: Houshang
authors.forename: Reza
authors.initials: R
authors.lastname: Khodarahmi
authors.forename: Khodarahmi
authors.initials: K
authors.lastname: Reza
authors.forename: Masoud
authors.initials: M
authors.lastname: Sadeghi
authors.forename: Sadeghi
authors.initials: S
authors.lastname: Masoud
authors.forename: Ali
authors.initials: A
authors.lastname: Ebrahimi
authors.forename: Ebrahimi
authors.initials: E
authors.lastname: Ali
authors.forename: Mansour
authors.initials: M
authors.lastname: Rezaei
authors.forename: Rezaei
authors.initials: R
authors.lastname: Mansour
authors.forename: Asad
authors.initials: A
authors.lastname: Vaisi-Raygani
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000378:metabolism*; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D043303:Aryldialkylphosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D016022:Case-Control Studies; D002374:Catalase / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011565:Psoriasis / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood; D014527:Uric Acid / Q000097:blood; D055815:Young Adult
chemical_list: C505693:APOA1 protein, human; D000975:Antioxidants; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D014527:Uric Acid; D002374:Catalase; D013482:Superoxide Dismutase; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human; D001663:Bilirubin